Skip to main content

Vallon Pharmaceuticals, Inc. (VLON)

NASDAQ: VLON · IEX Real-Time Price · USD
5.10 -0.28 (-5.20%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap33.38M
Revenue (ttm)n/a
Net Income (ttm)-7.46M
Shares Out6.81M
EPS (ttm)-1.39
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume87,868
Open5.37
Previous Close5.38
Day's Range4.84 - 5.44
52-Week Range3.61 - 10.36
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 9, 2021

About VLON

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvan...

IndustryBiotechnology
IPO DateFeb 10, 2021
Employees2
Stock ExchangeNASDAQ
Ticker SymbolVLON
Full Company Profile

Financial Performance

Financial Statements

News

Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements

- L ead program, ADAIR , advancing toward completion of patient enrollment and treatment in ongoing SEAL study

1 week ago - GlobeNewsWire

Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board

- Inaugural a ppointments include globally renowned leaders and experts on attention-deficit/hyperactivity disorder (ADHD) and stimulant abuse

1 month ago - GlobeNewsWire

Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit

Live video webcast with David Baker, President and CEO of Vallon , on Wednesday , August 18 th 12 : 30 PM ET

2 months ago - GlobeNewsWire

Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021

2 months ago - GlobeNewsWire

Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for...

- Patent bolsters intellectual property protection as Company's partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK

3 months ago - GlobeNewsWire

Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

- Company remains on track to report p ivotal data from lead program , ADAIR, in second half 2021

5 months ago - GlobeNewsWire

Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer

- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm

5 months ago - GlobeNewsWire

Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit

Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET

5 months ago - GlobeNewsWire

Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum

David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on A pril 29 th at 10:30 AM ET

5 months ago - GlobeNewsWire

Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Ap...

- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021 - Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines ...

6 months ago - GlobeNewsWire

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday Morning

Pre-market movers on Tuesday include ZOM stock, RIOT stock and AGC stock, following all sorts of big stock market news. The post Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tue...

6 months ago - InvestorPlace

Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update

- Pivotal data from lead program, ADAIR, expected in second half 2021

6 months ago - GlobeNewsWire

Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the developm...

7 months ago - GlobeNewsWire

Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors

- Accomplished executive leader with more than 30 years of experience in finance and operations

8 months ago - GlobeNewsWire

Vallon Pharmaceuticals Announces Closing of Initial Public Offering

PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the developmen...

8 months ago - GlobeNewsWire

Vallon Pharmaceuticals Announces Pricing of Initial Public Offering

PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are ...

8 months ago - GlobeNewsWire

Micro-cap drug developer Vallon Pharmaceuticals sets terms for $15 million IPO

Vallon Pharmaceuticals, a biopharma developing abuse-deterrent prescription drugs for CNS disorders, announced terms for its IPO on Thursday.

9 months ago - NASDAQ

Vallon Pharmaceuticals IPO Registration Document (S-1)

Vallon Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

9 months ago - SEC